Stock Watch

Daiichi Sankyo of Japan had been given the research division of Ranbaxy Laboratories for new drugs as part of an ongoing integration programme. Ranbaxy has now become a pure generic drug maker.

The Indian company will hold back its research activity for its anti-malarial new drug which is currently in Phase-III trials besides those molecules which are in advanced stages of development and those being developed in partnership with UK’s drug company GlaxoSmithKline. Ranbaxy did not provide financial details of the transaction.

Even as it reported a bottom-line twice that in the first three months ended, India’s largest drug maker, Ranbaxy Laboratories, has reported that it expects a net profit of Rs 460 crore in 2010. The Revenue during the quarter soared

India’s largest drug manufacturer, Ranbaxy Laboratories, recorded forth quarter profit of 9.6 billion rupees, beating streets estimate and overtaking the loss of 7.6 billion rupees during the same period last year.

Last year sales were 15.6 billion rupees which for current year jumped to 24.9 billion recording 65 percent increase.

"Solid growth in key geographies, along with optimal delivery value from first-to-file opportunities in the United States, ensured that we achieved yet another quarter of strong operational performance," said Atul Sobti, the company's chief executive.

Ranbaxy Laboratories today swung to a consolidated quarterly profit after tax of Rs 262 crore for the quarter ended December, 2009, triggered by the launch of its own copy of a blockbuster drug in the U. S., and forecast strong growth this year from new products.

Leading pharmaceutical company Ranbaxy Laboratories has announced to sell its 50 per cent stake in its Japanese joint venture with Nihon Pharmaceutical Industry (NPI) without divulging the financial details of the deal. However, media reports claim that the buyer Nippon Chemiphar, founded in 1950, would pay $18 million for the 50 per cent stake.

Ranbaxy Laboratories, India's largest pharmaceutical company, has finally got approval from the U. S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg in the market.

Indian markets closed above 15,000 level as buying was seen in major Banking, Metals and Capital Goods counters. Technical experts were expecting Indian markets to trade lower for the day as US markets closed lower on Monday and Asian stocks were seen lower during the start of session. However, markets surprised traders and started gaining momentum after first 30 minutes of trade.

Ranbaxy Laboratories, leading Indian drug manufacturer, has received US Food & Drug Administration's (USFDA) final approval to manufacture and sell Sumatriptan Succinate tablets.

The approval has been granted for tablets in potencies of 25 mg (base) and 50 mg (base).

India's largest pharmaceutical company Ranbaxy Laboratories clocked net loss of Rs 806.55 crore in the quarter ended December 2008 as against net profit of Rs 48.40 crore during the previous quarter ended December 2007.

In addition, the company's sales declined 2.00% to Rs 1012.72 crore in the quarter ended December 2008 as against Rs 1033.43 crore during the previous quarter ended December 2007.

Finally, Japan based drug maker Daiichi Sankyo has completed the acquisition process of Indian drug maker Ranbaxy Laboratories on Friday. The Japanese drug maker acquired remaining 11.4% stake for Rs 3,537.6 crore and its total stakes increased to 63.92%. 

Now, Daiichi has become the majority stake holder of the largest drug maker in the country. Singh family would still have some management roles in Ranbaxy. However, Ranbaxy would continue to work as an independent company.